10th week of 2009 patent applcation highlights part 64 |
Patent application number | Title | Published |
20090062298 | DEUTERIUM-ENRICHED SILDENAFIL - The present application describes deuterium-enriched sildenafil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062299 | DEUTERIUM-ENRICHED DOXAZOSIN - The present application describes deuterium-enriched doxazosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062300 | DEUTERIUM-ENRICHED PRAZOSIN - The present application describes deuterium-enriched prazosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062301 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JA K3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS - The present invention relates to a pharmaceutical combination comprising at least one PKC inhibitor, in particular indolylmaleimide derivatives, and at least one JAK3 kinase inhibitor and the uses of such a combination e.g. in autoimmune diseases, e.g. in preventing or treating type I diabetes mellitus and disorders associated therewith, or in transplantation. | 2009-03-05 |
20090062302 | Jak2 Tyrosine Kinase Inhibition - The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders. | 2009-03-05 |
20090062303 | DEUTERIUM-ENRICHED ZIPRASIDONE - The present application describes deuterium-enriched ziprasidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062304 | Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex - This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. | 2009-03-05 |
20090062305 | DEUTERIUM-ENRICHED CETIRIZINE - The present application describes deuterium-enriched cetirizine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062306 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME - A compound represented by the following general formula (I), wherein R | 2009-03-05 |
20090062307 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS - The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity. | 2009-03-05 |
20090062308 | METHODS OF USING SODIUM CHANNEL BLOCKERS - The present invention relates to use of a compound represented by formula (I): | 2009-03-05 |
20090062309 | Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor - A pharmaceutical composition comprising an effective amount of at least one (a) an effective amount of at least one 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazinecarboxamide monohydrochloride, dihydrate derivative comprising pirazinoylguanidine, benzamil, dichlorobenzamil, 5-(N,N-dimethyl)-Amiloride, 5-(N-ethyl-N-isopropyl)-Amiloride, (N,N-hexamethylene)-Amiloride, 5-(N-methyl-N-isobutyl)-Amiloride, and Amiloride citrate; (b) an effective amount of a calcium increasing agent; and (c) a pharmaceutically acceptable excipient. Methods are provided for treating a cardiovascular disease (CVD) in a patient diagnosed as having CVD or at risk for developing CVD, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one of 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazinecarboxamide monohydrochloride, dihydrate and/or a derivative thereof. | 2009-03-05 |
20090062310 | DEUTERIUM-ENRICHED VORICONAZOLE - The present application describes deuterium-enriched voriconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062311 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS - Inhibitors of HCV replication of formula (I) | 2009-03-05 |
20090062312 | DEUTERIUM-ENRICHED INDIPLON - The present application describes deuterium-enriched indiplon, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062313 | Pde5 inhibitor compositions and methods for treating cardiac indications - The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing a cardiac indication in a subject. | 2009-03-05 |
20090062314 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof - The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof. | 2009-03-05 |
20090062315 | Pharmaceutical Acceptable Composition Containing Non-Steroidal Anti-Inflammatory Drug and Local Anesthetics - A pharmaceutical acceptable composition is provided. The composition comprises an effective amount of a non-steroidal anti-inflammatory drug (NSAID), a local anesthetic, and an antiviral drug. | 2009-03-05 |
20090062316 | DEUTERIUM-ENRICHED PELITREXOL - The present application describes deuterium-enriched pelitrexol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062317 | MEDICINAL USE OF RECEPTOR LIGANDS - Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted phenyl or benz-fused 5 membered N-containing heterocycles defined in the specification; R, is attached to a ring carbon of ring B, and represents hydrogen, F, Cl, or —OCH | 2009-03-05 |
20090062318 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF - The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders. | 2009-03-05 |
20090062319 | METHODS OF INHIBITING THE INTERACTION BETWEEN S100 AND THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS - A method of inhibiting an interaction between a S100 protein and the receptor for advanced glycation end-products is provided comprising administering to a subject a therapeutically effective amount of cromolyn, C5, or salt, hydrate, or solvate thereof. In some embodiments, the S100 protein is S100P. In some embodiments, the S100 protein is S100P. In addition, the present invention provides a method of treating a cancer comprising administering to a mammal a therapeutically effective amount of cromolyn, C5, or salt, hydrate, or solvate thereof. Additional methods are also provided. | 2009-03-05 |
20090062320 | Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor - The disclosure includes a method of treating a warm-blooded animal having a disorder mediated by the fibroblast growth factor receptor (FGFR), in particular 8p11 myelo-proliferative syndrome (EMS), pituitary tumors, retinoblastoma, synovial sarcoma, chronic obstructive pulmonary disease (COPD), seborrheic keratosis, obesity, diabetes and related disorders, autosomal dominant hypophosphatemic Rickets (ADHR), X-chromosome linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO) and fibrous dysplasia of the bone (FD), as well as to a method of promoting localized neochondrogenesis, as well as a method of treating hepatocellular carcinoma, lung cancer, especially pulmonary adnocarcinoma, oral squameous cell carcinoma, or esophageal squameous cell carcinoma, or any combination of two or more such diseases. | 2009-03-05 |
20090062321 | Hydroxybenzoate Salts Of Metanicotine Compounds - Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form. | 2009-03-05 |
20090062322 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines - The invention provides compounds of formula (I) | 2009-03-05 |
20090062323 | DEUTERIUM-ENRICHED IRINOTECAN - The present application describes deuterium-enriched irinotecan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062324 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF - The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy. | 2009-03-05 |
20090062326 | M3 MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF M3 MUSCARINIC RECEPTOR-EXPRESSING TUMORS - The present disclosure provides methods of treating a tumor using M3 muscarininc receptor antagonists, such as darifenacin. In some examples, the tumor expresses M3 muscarinic receptors, such as tumors associated with smoking. Also provided are compositions that can be used to practice such methods. | 2009-03-05 |
20090062327 | Inhibitors of AKT Activity - The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer. | 2009-03-05 |
20090062328 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods - Imidazo[4,5-c] ring compounds, (e.g. imidazo[4,5-c]pyridines, imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridine, and 6,7,8,9-tetrahydro imidazo[4,5-c]naphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 2009-03-05 |
20090062329 | BISNAPHTHALIMIDOPROPYL DERIVATIVE COMPOUNDS WITH ANTI-PARASITE AND ANTI-CANCER ACTIVITY - The bisnaphthalimidopropyl derivatives with anti-parasitic and anti-cancer activity. Bisnaphthalimidopropyl derivatives (A) BNIPPut, BNIPDapen, BNIPDhex, BNIPDahep, BNIPDaoct, BNIPDanon, BNTPDadec, BNIPDadod, BNPDpta, BNIPDeta were synthesized in yields ranging from 50-70 and their cytotoxicity against colon cancer cells (CaCo-2) and the parasite | 2009-03-05 |
20090062330 | TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST - Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine). | 2009-03-05 |
20090062331 | DEUTERIUM-ENRICHED MARAVIROC - The present application describes deuterium-enriched maraviroc, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062336 | Methods of Diminishing Co-Abuse Potential - Methods of diminishing or eliminating the co-abuse of a methylphenidate drug comprising identifying a patient or patient group suspected or likely to abuse said methylphenidate drug in combination with a substance known or suspected to give rise to l-ethylphenidate or psychotropic effect when ingested in the combination and making available to said patent or patient group said methylphenidate drug substantially free of l-threo methylphenidate. | 2009-03-05 |
20090062337 | Treatment of Microbial Infections - The present invention provides methods for treating various microbial infections using a compound of the formula: | 2009-03-05 |
20090062338 | NITROXIDES FOR USE IN TREATING OR PREVENTING CARDIOVASCULAR DISEASE - Pharmaceutical compositions are provided that are useful in treating cardiovascular disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cardiovascular disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of cardiovascular disease. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the cardiovascular disease is myocardial infarction. | 2009-03-05 |
20090062339 | COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS - The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro. | 2009-03-05 |
20090062340 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF - Novel biaromatic compounds having the structural formula (I) below: | 2009-03-05 |
20090062341 | Nuclear receptor binding agents - The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity. | 2009-03-05 |
20090062342 | AMINES - The invention relates to novel amine derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin. | 2009-03-05 |
20090062343 | Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindol-2-yl)-piperidine-2,6-dione - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 2009-03-05 |
20090062344 | THERAPEUTIC SUBSTITUTED PIPERIDONE COMPOUNDS - Compounds comprising | 2009-03-05 |
20090062345 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 2009-03-05 |
20090062346 | DEUTERIUM-ENRICHED TIPRANAVIR - The present application describes deuterium-enriched tipranavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062347 | DEUTERIUM-ENRICHED AXITINIB - The present application describes deuterium-enriched axitinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062348 | Antifungal Agent Containing Pyridine Derivative - The present invention provides an antifungal agent that has superior antifungal action and is also superior in terms of physical properties, safety and metabolic stability. The present invention discloses a compound represented by the formula (I): | 2009-03-05 |
20090062349 | 1-Hydroxycycloalkanecarboxamide derivatives - α-Hydroxycycloalkanecarboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein formula (a) is a single or double bond; R | 2009-03-05 |
20090062350 | Pesticidal composition - A pesticidal composition including a microcapsule in which an oil containing a pesticidal active ingredient and an organic solvent is covered with a wall made of a thermosetting resin; at least one kind selected from the group consisting of polyglycerin fatty acid ester, sucrose fatty acid ester and alkylbenzenesulfonic acid or its salt; a thickener, and water is provided. The pesticidal composition has elution performance suited for an applied situation without the need of changing the design of the microcapsule itself As the thermosetting resin, a polyurethane resin or a polyurea resin is preferred. As the pesticidal active ingredient, an insect growth regulating active ingredient such as 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether can be recited. | 2009-03-05 |
20090062351 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators - A compound of Formula (I): Formula (I) wherein: R | 2009-03-05 |
20090062352 | DEUTERIUM-ENRICHED AMLODIPINE - The present application describes deuterium-enriched amlodipine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062353 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders - Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions. | 2009-03-05 |
20090062354 | Method of increasing the extent of absorption of tizanidine - An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 2009-03-05 |
20090062355 | Pharmaceutical Product - An agent for suppressing the production of various cytokines (IL-8 and the like) and inflammatory mediators, an agent for suppressing the expression of COX-II and the like, or an inhibitor of various phosphorylation enzymes (ATF2 and the like), which contains a TLR signaling inhibitory substance, preferably a compound represented by the formula (I) or the formula (II) | 2009-03-05 |
20090062356 | SUBSTITUTED BENZIMIDAZOLE DERIVATIVES - The invention is concerned with novel substituted benzimidazole derivatives of formula (I) | 2009-03-05 |
20090062357 | DEUTERIUM-ENRICHED FLUCONAZOLE - The present application describes deuterium-enriched fluconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062358 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS - The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, | 2009-03-05 |
20090062359 | Injectable capsaicin with non-local anesthetic sodium channel-blocker adjunctive agent - Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a non-anesthetic sodium channel blocker. | 2009-03-05 |
20090062360 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof - Compounds of formula (I) and salts and solvates thereof are provided: | 2009-03-05 |
20090062361 | THERAPEUTIC HYDANTOINS - Disclosed herein is a compound represented by a formula | 2009-03-05 |
20090062362 | Veterinary Formulation for Administration of a Water-Insoluble Drug to a Target Animal Through a Water Distribution System - This invention concerns a method for the preparation of a suspoemulsion formulation, which can be easily produced on an industrial scale and which allows the reproducible and effective administration of one or more water-insoluble veterinary drugs through water distribution systems. The water-insoluble veterinary drug, in finely ground form, is dispersed in a water immiscible liquid, followed by homogenisation of this system into a water phase. To facilitate the preparation of a stable formulation, one or more stabilising agents such as emulsifiers, thickeners, anti-oxidants and anti-microbials can be used. The resulting suspoemulsion shows excellent long term storage stability and a good “in use” stability after dilution in a vessel and during all handling and transport in the water distribution system. | 2009-03-05 |
20090062363 | AMIDE DERIVATIVE OR SALT THEREOF - [Problem] To provide a compound which can be used for the prevention and/or treatment of diseases in which 5-HT | 2009-03-05 |
20090062364 | DEUTERIUM-ENRICHED CELECOXIB - The present application describes deuterium-enriched celecoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062365 | Pyrazoles for the Treatment of GERD and IBS - The present invention relates to novel pyrazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R | 2009-03-05 |
20090062366 | Pyrrolidine derivative or salt thereof - [Problem] To provide a compound which may be used in treating diseases in which a calcium sensing receptor (CaSR) is concerned, particularly hyperparathyroidism. | 2009-03-05 |
20090062367 | DEUTERIUM-ENRICHED ELETRIPTAN - The present application describes deuterium-enriched eletriptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062368 | DEUTERIUM-ENRICHED SUNITINIB - The present application describes deuterium-enriched sunitinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062369 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS - Administration of sPLA | 2009-03-05 |
20090062370 | Method for increasing the speed of recovery and/or the speed of wound healing of injured animals - This invention is in the field of animal food, in particular food for wounded animals. Surprisingly, it has now been found that the speed of recovery of wounded animals may be increased by feeding the animal with a certain amount of natural occurring immune enhancing ingredients such as beta-glucans and/or phytohormones like auxin or gibberellic acid. Also, combinations of these substances, in particular the combination of beta-glucans and phytohormones, were shown to have a synergistic effect in that they improved the recovery speed of the animal more than the individual components on their own. | 2009-03-05 |
20090062371 | ORAL PREPARATION FOR PROMOTING SYNTHESIS OF TISSUE COLLAGEN - An object of the present invention is to provide an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, which is safe and has an excellent effect. The present invention can provide an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, which comprises hydroxyproline or a salt thereof as an active ingredient. | 2009-03-05 |
20090062372 | Glycopyrronium Salts and Their Therapeutic Use - A glycopyrronium salt such as glycopyrronium iodide has a lower glass transition temperature than glycopyrronium bromide. It is therefore more suitable for formulation. | 2009-03-05 |
20090062373 | DEUTERIUM-ENRICHED PF-184298 - The present application describes deuterium-enriched PF-184298, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062374 | DEUTERIUM-ENRICHED LASOFOXIFENE - The present application describes deuterium-enriched lasofoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062375 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES - The invention provides a method of treating viral haemorrhagic fevers, such as that caused by Dengue virus, which comprises administering a composition comprising a pharmaceutically active amount of a matrix metalloproteinase inhibitor. | 2009-03-05 |
20090062376 | Preparation of Taxanes From 9-Dihydro-13-Acetylbaccatin III - The present invention relates to a new process for the preparation of 9-dihydrobaccatin III intermediates as useful precursors for the preparation of paclitaxel, 1, docetaxel, 2, and analogues thereof. More particularly, the process comprises the steps of (i) concomitantly deacetylating esters at the 10-position and 13-position of 9-dihydro-13-acetylbaccatin III to form 9-dihydro-10-deacetylbaccatin III; (ii) protecting a hydroxy group at the 7-position of 9-dihydro-10-deacetylbaccatin III; and (iii) acylating a hydroxy group at the 10-position to form a compound of formula II. | 2009-03-05 |
20090062377 | ANTI-CANCER COMBINATIONS - The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations. | 2009-03-05 |
20090062378 | Nutraceutical Mangosteen Composition - Nutraceutical compositions derived from the fruit of the | 2009-03-05 |
20090062379 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISORDERS - Green tea polyphenol compositions and methods of their use are provided. Certain aspects provide methods for modulating expression of one or more autoantigens using the disclosed green tea polyphenol compositions. Representative green tea polyphenols include, but are not limited to (−)-epigallocatechin-3-gallate. Other aspects provide methods for treating autoimmune disease. | 2009-03-05 |
20090062380 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - The invention relates to the medical use of natural isoflavones and their semisynthetic derivatives or the pharmaceutically acceptable salts thereof for the therapeutic and/or prophylactic treatment of diseases, at the base of which lies an excessive production or storage of glycosaminoglycans, especially for treatment of mucopolysaccharidoses. The isoflavones and their semisynthetic derivatives are represented by formula (I), in which R | 2009-03-05 |
20090062381 | AQUEOUS COMPOSITION - In an aqueous composition comprising a 15-keto-prostaglandin compound as an active ingredient, a polyoxyethylene castor oil derivative is admixed. By admixing a polyoxyethylene castor oil derivative, the solubility of the 15-keto-PG compound in water is increased. In a preferable embodiment, the aqueous composition may further comprise a quaternary ammonium type cationic surface active agent as a preservative. The composition of this embodiment exhibits high antimicrobial preservative effectiveness against indigenous bacterium in the eyes such as | 2009-03-05 |
20090062382 | EXTERNAL PREPARATION FOR IMPROVING COITAL FUNCTION - The present invention provides a preventive or a remedy for penile erectile dysfunction, which promotes blood-flow in a penile sponge body over long time and thus induces erection while showing high safety without any adverse effect on a body as a whole, when externally administered to a penis. | 2009-03-05 |
20090062383 | Salts of Substituted Allophanates and Their Use in Drugs - The present invention relates to salts of substituted allophanates, methods for their production, medicaments containing said compounds and the use of said compound for the production of medicaments. | 2009-03-05 |
20090062384 | NOVEL ABIETANE DITERPENOID COMPOUND, AND COMPOSITION COMPRISING EXTRACT OF TORREYA NUCIFERA, OR ABIETANE DITERPENOID COMPOUNDS OR TERPENOID COMPOUNDS ISOLATED FROM THEM FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE - The present invention relates to a composition for the prevention and the treatment of cardiovascular disease containing extracts of | 2009-03-05 |
20090062385 | DEUTERIUM-ENRICHED FESOTERODINE - The present application describes deuterium-enriched fesoterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062386 | Simulants of Toxants for Training and Testing - Compositions are formulated with generally regarded as safe (GRAS) ingredients for use as chemical simulants of toxants such as chemical warfare agents. The compositions can be used for training exercises, testing, and research studies and they can be applied safely to human skin. They include ultraviolet-excited fluorescent ingredients that make possible visible viewing of the simulants. The chemical simulants have good fidelity with the physical properties of toxants, for example, vapor pressure, volatility, persistence, viscosity, response to oxidative, hydrolysis, and perhydrolysis decontaminants, and they can be detected by commonly used portable instruments used to detect toxants. | 2009-03-05 |
20090062387 | METHOD OF PREVENTING NEPHROCALCINOSIS - The present invention provides the invention provides methods of reducing phosphate nephropathy in a mammal suffering from impairment of renal function, including administering to the mammal an amount of citrate that is effective to reduce serum phosphorous concentration. | 2009-03-05 |
20090062388 | Use of acetyl L-carnitine for the preparation of a medication for the preventive therapy for pain - The invention relates to the use of the acetyl L-carnitine, or a pharmaceutically acceptable salt thereof for the preparation of a medication for the preventive therapy for pain. | 2009-03-05 |
20090062389 | In-Shower Lotion Compositions Comprising Up to 10% Free Fatty Acids Wherein Ratio of Unsaturated to Saturated Fatty Acids is at Least 1:1 - This invention relates to rinse-off skin conditioning compositions comprising relatively low amounts of oil/emollient and relatively low amounts of aqueous phase stabilizer/structurant. Use of unsaturated fatty acid (or at least minimum amount of unsaturated fatty acid as percentage of total fatty acid) has been found to result in unexpectedly high hydration. In a second embodiment, use of branched fatty acid (at minimum amount branched as percentage of total) also results in superior hydration. Also mixtures of unsaturated and branched fatty acids can be used. | 2009-03-05 |
20090062390 | IN-SHOWER LOTION COMPOSITIONS COMPRISING UP TO 10% FREE FATTY ACIDS WHEREIN RATIO OF UNSATURATED TO SATURATED FATTY ACIDS IS AT LEAST 1:1 - This invention relates to rinse-off skin conditioning compositions comprising relatively low amounts of oil/emollient and relatively low amounts of aqueous phase stabilizer/structurant. Use of unsaturated fatty acid (or at least minimum amount of unsaturated fatty acid as percentage of total fatty acid) has been found to result in unexpectedly high hydration. In a second embodiment, use of branched fatty acid (at minimum amount branched as percentage of total) also results in superior hydration. Also mixtures of unsaturated and branched fatty acids can be used. | 2009-03-05 |
20090062391 | Use of a virucidal ointment in the nares for prevention of transmission and contraction of common colds - A novel method of preventing or inhibiting the contraction or communication of viruses which cause the common cold is proposed. Application of a virucidal ointment containing one or more organic acids (e.g. malic acid) with or without a surfactant (e.g. sodium C.sub.14-C.sub.16 olefin sulfonate) in a carrier agent (e.g. petrolatum) to the nares of well individuals will reduce the chance that they contract illness with the viruses which cause colds. Application of said ointment to the nares of individuals with a cold will reduce the chance they transmit the illness by reducing self-contamination of their hands when touching their nose. The ointment is most effective when applied with a clean applicator multiple times daily. | 2009-03-05 |
20090062392 | DEUTERIUM-ENRICHED GABAPENTIN - The present application describes deuterium-enriched gabapentin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062393 | DEUTERIUM-ENRICHED PREGABALIN - The present application describes deuterium-enriched pregabalin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062394 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES - A topical or transdermal composition including a polar derivative of ketoprofen and a pharmaceutically acceptable topical or transdermal carrier, wherein the polar derivative of ketoprofen comprises a polarity that is greater than that of ketoprofen. | 2009-03-05 |
20090062395 | RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION - The present invention relates to methods for the prevention of, delay progression to or treatment of hypertension, comprising administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof as well as methods of preventing secondary complications linked to cessation of the treatment of hypertension. | 2009-03-05 |
20090062396 | Novel Haloalkoxy-Substituted Salicylic Anilides - The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or disorders associated therewith. | 2009-03-05 |
20090062397 | COMPOUNDS AND METHODS FOR ENHANCING SOLUBILITY OF FLORFENICOL AND STRUCTURALLY-RELATED ANTIBIOTICS USING CYCLODEXTRINS - The relatively low solubility of florfenicol (FEC) in water (1.3 mg/mL) limits its use in medicated drinking water systems for treatment of pulmonary disease of swine and poultry. Current formulations use a high volume organic solvent to reach the required FFC concentration of 13.5 mg/mL in an automated proportioner mixing tank system, with practical disadvantages for the users in the field. This invention relates to the effects of complex formation with natural and modified cyclodextrins on the aqueous solubility of FFC and antibiotics of related structure. Furthermore, this invention relates to the effects of polyethylene glycol (PEG-300) as a co-solvent in an FFC-cyclodextrin system to achieve the required FFC dose in the mixing tank system and to avoid high volumes of the organic solvent. | 2009-03-05 |
20090062398 | DEUTERIUM-ENRICHED TOLTERODINE - The present application describes deuterium-enriched tolterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062399 | DEUTERIUM-ENRICHED SERTRALINE - The present application describes deuterium-enriched sertraline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-05 |
20090062400 | Method of treating glaucoma using rasagiline - Disclosed is a method of reducing glaucoma in a subject afflicted with glaucoma, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to reduce glaucoma. | 2009-03-05 |
20090062401 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS - The present invention relates to compounds having a decaline scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said decaline-derived compounds can be used for prophylaxsis and/or treatment of diabetes mellitus type I, diabetes mellitus type II, tuberculosis and other infectious diseases, proliferative diseases, cancer, neurodegenerative diseases, obesity, cognitive dysfunctions and metabolic syndromes. | 2009-03-05 |
20090062402 | ACTIVE SUBSTANCE COMBINATION OF LICOCHALCONE A AND PHENOXYETHANOL - A method for the prophylaxis or treatment of inflammatory skin conditions, which method comprises applying to the skin a cosmetic or pharmaceutical preparation comprising licochalcone A and phenoxyethanol. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way. | 2009-03-05 |